Delivery Order 75N91022D00016-75N91026F00001
Award Date 2/9/26
Potential Completion Date 5/9/26
Potential Value $68K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Chicago, IL 60616, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a $1,790,042.00 Delivery Order Contract awarded by the National Cancer Institute (NCI) to the IIT Research Institute (IITRI), a non-profit subsidiary of the Illinois Institute of Technology (IIT). The contract is for toxicology studies in mice and dogs administered MTX-531, which does not have a set-aside designation. IITRI is a leading preclinical contract research organization that specializes in providing drug development services to federal agencies like the NCI, NIAID, NINDS, and...
- The National Cancer Institute awarded a definitive cost-plus-fixed-fee contract to IIT Research Institute (IITRI), a non-profit contract research organization and subsidiary of the Illinois Institute of Technology, for preclinical toxicology and pharmacology services supporting drug development for cancer, AIDS, and AIDS-related illnesses. The contract, awarded on April 1, 2004, carries a ceiling value of $159.3 million with an ultimate completion date of June 30, 2016, and will be performed...
- This is a firm fixed price delivery order awarded by the National Cancer Institute (NCI) to IIT Research Institute (IITRI), a non-profit preclinical contract research organization (CRO). The contract is for $532,562.26 to evaluate a breast cancer prevention agent under the PREVENT Cancer Preclinical Drug Development Program, a $149.995 million NCI Indefinite Delivery Vehicle (IDV) that IITRI holds. IITRI has extensive experience providing preclinical drug development services to federal agencies...
- This is a firm fixed-price delivery order awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to the IIT Research Institute (IITRI), a non-profit contract research organization. The $4,145 contract is for a pre-clinical toxicology study of a drug developed for cancer patients, as part of the Toxicology of Drugs Developed for Cancer Patients contract vehicle. IITRI specializes in preclinical drug development services and has...
- This federal contract award is for $2,708.00 to the IIT Research Institute (IITRI), a non-profit division of the Illinois Institute of Technology (IIT), to provide contract orientation and kickoff meeting services for R&D under the "Preclinical Toxicology of Small Molecule Drugs Developed for Cancer and Other Indications" program. The contract is being issued by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services. IITRI...
- The National Cancer Institute, a component of the National Institutes of Health within the Department of Health and Human Services, awarded a $2.4 million delivery order against the Toxicology of Drugs Developed for Cancer Patients master IDIQ contract to IIT Research Institute. Under this order, IIT Research Institute will provide toxicology services to support the preclinical development of EIF4A inhibitors rocaglamide and didesmethylrocaglamide from September 2020 through September 2023 in...
- IIT Research Institute (IITRI), a nonprofit contract research organization and subsidiary of the Illinois Institute of Technology, was awarded a $231.5K firm fixed-price contract by the National Cancer Institute (NCI) on September 30, 2004, to conduct preclinical toxicology studies of chemopreventive agents in dogs as part of Work Statement #62. The contract, which was completed on June 30, 2005, and performed in Illinois, represents IITRI's core competency in providing specialized preclinical...
- This is a firm fixed price delivery order awarded by the National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, to IIT Research Institute. The order is for preclinical efficacy evaluation of a lipid-based SMEDDS formulation of the drug compound DIM, BR-9001, as part of the NCI's Preclinical Prevent Cancer Program. The $970,988.47 contract has a completion date of February 7, 2022. IIT Research Institute is a non-profit research...
- This is a $631,772.00 delivery order contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to the IIT Research Institute (IITRI), a non-profit contract research organization. The contract is for toxicology studies on reproductive effects in rats, supporting the NCCIH (National Center for Complementary and Integrative Health) program. This is a cost-plus-fixed-fee contract that was not set aside for any type of small...
- This is a $1,886,133.00 Cost Plus Fixed Fee delivery order contract awarded by the National Cancer Institute (NCI) to the IIT Research Institute (IITRI), a division of the Illinois Institute of Technology (IIT), to conduct toxicology studies in rats and dogs administered the drug candidate AIT-102. The contract has an ultimate completion date of March 31, 2026. IITRI is a non-profit contract research organization that specializes in preclinical drug development services for federal agencies,...